Metraipolis › archive › dc_613abdafa2ce

Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease — Europe PMC PMID:40932851

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40932851
DOI: 10.1016/j.eclinm.2025.103465
License (as archived): solo-consultazione
Archived: 2026-11-10T06:23:44.735Z
SHA-256 of the archived text: 6299d62ae11efea60b88e3b4cf835d5d1e8f08e7dfd1b79ddf459fa330043fd8
Stable URL of this page: https://metraipolis.com/documento/dc_613abdafa2ce

How to cite

Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease — Europe PMC PMID:40932851 — Europe PMC (en), https://europepmc.org/article/MED/40932851 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_613abdafa2ce (Metraipolis archive dc_613abdafa2ce, sha256 6299d62ae11efea60b88e3b4cf835d5d1e8f08e7dfd1b79ddf459fa330043fd8)

BibTeX

@misc{dc613abdafa2ce,
  title = {Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease — Europe PMC PMID:40932851},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40932851},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_613abdafa2ce; sha256 6299d62ae11efea60b88e3b4cf835d5d1e8f08e7dfd1b79ddf459fa330043fd8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40932851. Agents can read the archived copy with the MCP tool read_document.